In light of claims of improved efficacy and lower incidence of adverse effects compared with older drugs, second-generation antipsychotics have emerged as the predominant treatment for schizophrenia.

We analysed data from 7,216,791 people aged three to 18 years old. In the UK, antipsychotics, also known as “major tranquillisers”, are approved for use in under-18s with psychosis or with severely ...

A new study has found that adults with depression who start treatment with newer antipsychotic medications may face a higher ...

For 35 years, the FDA has placed onerous restrictions on the only drug it has ever approved for treatment-resistant ...

Psychiatric medication prescriptions to children and teenagers have more than doubled in the past 10 years amid a growing mental health "crisis" among Australia's youth. New government data shows ...

Recently, second-generation antipsychotics (SGAs), olanzapine plus fluoxetine, quetiapine extended release and aripiprazole have clearly demonstrated efficacy in the treatment of MDD patients ...

Medics should be “cautious” when prescribing antipsychotic medication for dementia patients, experts have said, after a new study found that using the drugs can put patients at risk of a horde ...

Although antipsychotics were developed to treat schizophrenia, newer ones are sometimes used to treat depression that has not been relieved by antidepressants or other treatments. Depression is a ...

conventional agents All-cause mortality as recorded in the Registered Persons Database or the Discharge Abstract Database New use of atypical antipsychotics associated with SS increase in the risk ...

Semaglutide injectables like Ozempic, Wegovy and Mounjaro have revolutionized how doctors treat diabetes and obesity. The drug has become a popular weight-loss tool, buoyed by its popularity among ...

In fact, pharmaceutical companies have issued the strongest-possible warnings about the use of antipsychotics on their labelling. It is known as a black-box warning. “Elderly patients with dementia ...